TOVX Stock Summary and Trading Ideas (Theriva Biologics | AMEX:TOVX)

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

Theriva Biologics trades on the AMEX stock market under the symbol TOVX.

As of June 18, 2026, TOVX stock price declined to $0.25 with 1,415,899 million shares trading.

TOVX has a beta of 1.12, meaning it tends to be more sensitive to market movements. TOVX has a correlation of 0.02 to the broad based SPY ETF.

TOVX has a market cap of $11.52 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, TOVX traded as high as $30.00 and as low as $.16.

The top ETF exchange traded funds that TOVX belongs to (by Net Assets): VXF.

TOVX has underperformed the market in the last year with a price return of -46.0% while the SPY ETF gained +26.2%. However, in the short term, TOVX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +35.1% vs +11.6% return in SPY. But in the last 2 weeks, TOVX shares have been beat by the market, returning -12.8% compared to an SPY return of -1.0%.

TOVX support price is $.25 and resistance is $.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TOVX shares will trade within this expected range on the day.